Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
about
Hepatoprotectant ursodeoxycholyl lysophosphatidylethanolamide increasing phosphatidylcholine levels as a potential therapy of acute liver injuryProgression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice.Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosisOmega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.Cutting-edge issues in primary biliary cirrhosis.Mechanisms of tissue injury in autoimmune liver diseases.Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.Elevated cholesterol levels have a poor prognosis in a cholestasis scenario.Ursodeoxycholyl lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins.Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.Comparison of different bile acid-phospholipid conjugates in acute hepatitis.Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation.Trials and tribulations in drug development for nonalcoholic steatohepatitis.Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation.Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.Phospholipase A2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A2 Inhibitors.
P2860
Q28396783-06E6B500-EF93-4C4D-BC79-51416B2330C7Q33863032-DB9A9DBC-9A1F-403E-A775-BFB239A7E4C5Q34101451-55AF023D-A9B1-4FC1-B056-9D9AD999EFF8Q34760318-1DFAD673-A71C-4F4F-8408-2D3054ED04A4Q37729227-17126863-0CC3-4F03-B6FE-A2AA852C52CCQ37829668-6EEFBC03-6C8B-4E69-A62A-E6F0069D6336Q38235918-CA62FF18-809F-4C98-98CA-38247C9887DDQ38552201-A5F9ECC2-0B7D-4F7A-A5C6-076F9DE11C28Q38925850-728F80AA-4F00-4009-BC1F-CB63B85B0EA2Q38965833-441D640D-6B7A-41D4-B7AE-8A0C45F86DFFQ38973928-F7D2699A-C635-4279-8686-F14BC20F08A5Q39517348-E3802128-36CC-4B5C-A911-4B83AE03AE56Q40587873-6F2515DB-11C1-4FC1-BB32-CEF8CABE2D2EQ42735901-CD5EF374-8A6D-42F6-99FD-4BD528C3821DQ44206097-63BE412E-E790-4B2A-8FE1-A46A71E76279Q46710065-74F7D437-0BCD-49A2-89D2-E5840C873223Q55074125-2BF59AC3-6CA6-440D-A0ED-A0091F56B62AQ55234705-516AA74D-42D8-4F01-993D-AF3A7F13859BQ55345070-86FEF6B0-6C0E-4B20-BB27-E94AD17021C1
P2860
Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@en
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@nl
type
label
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@en
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@nl
prefLabel
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@en
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@nl
P2093
P2860
P356
P1433
P1476
Bile salt-phospholipid conjuga ...... e as a hepatoprotective agent.
@en
P2093
Anita Pathil
Tobias Rehlen
Walee Chamulitrat
Wolfgang Stremmel
P2860
P304
P356
10.1002/HEP.22955
P407
P577
2009-07-01T00:00:00Z